PFE · News · 20260806N

Revenue Performance and Mix

PFIZER INC · 2026-08-06 · Importance 31 · Surprise 32

Pfizer reported second-quarter 2026 revenue of $15.03 billion, up 3% year over year and above the $14.40 billion FactSet estimate. Non-COVID products increased 5% operationally, while total revenue increased 1% operationally because declining COVID-19 product sales offset growth elsewhere. Oncology products and newer medicines including Nurtec, Lorbrena and Padcev drove growth, while Eliquis demand remained strong. Tafamidis franchise sales reached $1.76 billion, up 10% sequentially.

Key facts

• Pfizer reported sales of the tafamidis franchise were $1.76 billion in Q2, up 10% quarter-over-quarter. source